BioCryst Pharma (BCRX) Posts Narrower than Expected Q1 Loss of 13c/Share; Reaffirms
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.70 +2.35%
Revenue Growth %: +13.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +13.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q1 EPS of ($0.13), $0.13 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $5.9 million.
BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
